Payment overview · 2025
General Payments
$100,409.91
85 reported records · 14 companies
Healthcare provider profile · identity verified
Marc Andrew Riedl, MD
Allopathic & Osteopathic Physicians|Allergy & Immunology · SAN DIEGO, CA · NPI 1285654889
Verified facts
What the public records show
CMS Open Payments records show Marc Andrew Riedl, MD received $100,409.91 in general payments during 2025 across 85 reported records.
CSL Behring accounted for 37.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gammagard Liquid, Orladeyo, Takhzyro.
BioCryst Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORLADEYO as an associated drug or biological on 272 records involving 71 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Orladeyo by this doctor in 2024.
BioCryst US Sales Co., LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORLADEYO as an associated drug or biological on 6240 records involving 2093 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Orladeyo by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Haegarda as an associated drug or biological on 3692 records involving 1703 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Haegarda by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Hizentra as an associated drug or biological on 13634 records involving 4691 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Hizentra by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XOLAIR as an associated drug or biological on 5293 records involving 2861 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Xolair by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CUVITRU as an associated drug or biological on 7118 records involving 2610 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Cuvitru by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Gammagard Liquid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TAKHZYRO as an associated drug or biological on 3355 records involving 1604 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Takhzyro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| CSL Behring | Unresolved — no canonical attribution shown | $37,702.97 | 37.5% | 23 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $16,535.79 | 16.5% | 15 | 2025 |
| Pharming Healthcare, Inc. | Unresolved — no canonical attribution shown | $9,379.78 | 9.3% | 10 | 2025 |
| Ionis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $8,827.75 | 8.8% | 3 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $8,168.37 | 8.1% | 5 | 2025 |
| BioCryst Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $8,012.51 | 8.0% | 13 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $5,535.63 | 5.5% | 2 | 2025 |
| Theratechnologies Inc. | Unresolved — no canonical attribution shown | $4,170.00 | 4.2% | 1 | 2025 |
| BioCryst US Sales Co., LLC | Unresolved — no canonical attribution shown | $727.98 | 0.7% | 7 | 2025 |
| Grifols Shared Services North America, Inc. | Unresolved — no canonical attribution shown | $712.50 | 0.7% | 1 | 2025 |
| AQUESTIVE THERAPEUTICS, INC. | Unresolved — no canonical attribution shown | $336.98 | 0.3% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $185.14 | 0.2% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $77.72 | 0.1% | 1 | 2025 |
| Kedrion Biopharma, Inc. | Unresolved — no canonical attribution shown | $36.79 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $49,967.18 | 15 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $38,047.02 | 15 |
| Travel and Lodging | $5,446.28 | 13 |
| Honoraria | $4,170.00 | 1 |
| Food and Beverage | $2,779.43 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Andembry Normalized: andembry |
Biological | CSL Behring | $33,748.47 | 21 | 2025 |
Source payment records
|
|||||
| TAKHZYRO Normalized: takhzyro |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $15,923.84 | 12 | 2025 |
Source payment records
|
|||||
| Xembify Normalized: xembify |
Biological | Grifols Shared Services North America, Inc., Grifols USA, LLC | $8,880.87 | 6 | 2025 |
Source payment records
|
|||||
| DONIDALORSEN Normalized: donidalorsen |
Drug | Ionis Pharmaceuticals, Inc. | $8,340.00 | 2 | 2025 |
Source payment records
|
|||||
| RUCONEST Normalized: ruconest |
Biological | Pharming Healthcare, Inc. | $7,779.78 | 9 | 2025 |
Source payment records
|
|||||
| DAWNZERA Normalized: dawnzera |
Drug | Ionis Pharmaceuticals, Inc., Theratechnologies Inc. | $4,657.75 | 2 | 2025 |
Source payment records
|
|||||
| ORLADEYO Normalized: orladeyo |
Drug | BioCryst Pharmaceuticals, Inc., BioCryst US Sales Co., LLC | $4,592.24 | 9 | 2025 |
Source payment records
|
|||||
| JOENJA Normalized: joenja |
Drug | Pharming Healthcare, Inc. | $1,600.00 | 1 | 2025 |
Source payment records
|
|||||
| GAMMAGARD LIQUID Normalized: gammagard liquid |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $536.25 | 1 | 2025 |
Source payment records
|
|||||
| LIBERVANT Normalized: libervant |
Drug | AQUESTIVE THERAPEUTICS, INC. | $336.98 | 1 | 2025 |
Source payment records
|
|||||
| Sajazir Normalized: sajazir |
Drug | Cycle Pharmaceuticals Inc | $185.14 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $77.72 | 1 | 2025 |
Source payment records
|
|||||
| Albuked Normalized: albuked |
Biological | Kedrion Biopharma, Inc. | $36.79 | 1 | 2025 |
Source payment records
|
|||||
| GAMMAKED Normalized: gammaked |
Biological | Kedrion Biopharma, Inc. | $36.79 | 1 | 2025 |
Source payment records
|
|||||
| KEDRAB Normalized: kedrab |
Biological | Kedrion Biopharma, Inc. | $36.79 | 1 | 2025 |
Source payment records
|
|||||
| KOATE Normalized: koate |
Biological | Kedrion Biopharma, Inc. | $36.79 | 1 | 2025 |
Source payment records
|
|||||
| RhoGAM Ultra-Filtered PLUS Normalized: rhogam ultra filtered plus |
Biological | Kedrion Biopharma, Inc. | $36.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GAMMAGARD LIQUID gammagard liquid |
2025 | Gammagard Liquid | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ORLADEYO orladeyo |
2025 | Orladeyo | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TAKHZYRO takhzyro |
2025 | Takhzyro | 2024 | 121 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| BioCryst Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | ORLADEYO open payments reported associated product |
CMS Open Payments — General Payments 272 supporting records · 71 recipient NPIs · example record 1222001445 |
Orladeyo · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| BioCryst US Sales Co., LLC Exact reporting entity; no affiliate inference |
2025 | ORLADEYO open payments reported associated product |
CMS Open Payments — General Payments 6240 supporting records · 2093 recipient NPIs · example record 1222001397 |
Orladeyo · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Haegarda open payments reported associated product |
CMS Open Payments — General Payments 3692 supporting records · 1703 recipient NPIs · example record 1232339032 |
Haegarda · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Hizentra open payments reported associated product |
CMS Open Payments — General Payments 13634 supporting records · 4691 recipient NPIs · example record 1232339012 |
Hizentra · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | XOLAIR open payments reported associated product |
CMS Open Payments — General Payments 5293 supporting records · 2861 recipient NPIs · example record 1200005083 |
Xolair · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | CUVITRU open payments reported associated product |
CMS Open Payments — General Payments 7118 supporting records · 2610 recipient NPIs · example record 1223616510 |
Cuvitru · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TAKHZYRO open payments reported associated product |
CMS Open Payments — General Payments 3355 supporting records · 1604 recipient NPIs · example record 1223616316 |
Takhzyro · 2024 Exact normalized brand match · 1 Part D row |
121 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Takhzyro | Lanadelumab-Flyo | 121 | 13 |
| Icatibant | Icatibant Acetate | 78 | 18 |
| Azelastine Hcl | Azelastine Hcl | 69 | 18 |
| Montelukast Sodium | Montelukast Sodium | 67 | 26 |
| Epinephrine | Epinephrine | 65 | 21 |
| Haegarda | C1 Esterase Inhibitor | 47 | suppressed |
| Dupixent Syringe | Dupilumab | 44 | suppressed |
| Cuvitru | Immun Glob G(Igg)/Gly/Iga Ov50 | 40 | suppressed |
| Firazyr | Icatibant Acetate | 35 | suppressed |
| Prednisone | Prednisone | 30 | 20 |
| Hizentra | Immun Glob G(Igg)/Pro/Iga 0-50 | 28 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 27 | suppressed |
| Berinert | C1 Esterase Inhibitor | 26 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | 12 |
| Xolair | Omalizumab | 18 | suppressed |
| Famotidine | Famotidine | 16 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 14 | suppressed |
| Orladeyo | Berotralstat Hydrochloride | 14 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $100,409.91 · 85 records | CSL Behring | Albuked, Andembry, DAWNZERA, DONIDALORSEN, DUPIXENT, GAMMAGARD LIQUID, GAMMAKED, JOENJA, KEDRAB, KOATE, LIBERVANT, ORLADEYO, RUCONEST, RhoGAM Ultra-Filtered PLUS, Sajazir, TAKHZYRO, Xembify | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gammagard Liquid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with BioCryst Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error